PRAX · NASDAQ · STOCK
Praxis Precision Medicines, Inc.
$370.53
52W $37.19 – $382.54
59/100
$10.33B
-28.6
2.78
Is PRAX Bullish or Bearish?
Mixed.
Innellis AI committee rates Praxis Precision Medicines, Inc. (PRAX) Watch with a composite score of 59/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +0.57 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -19.43 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 8.4x prices in significant intangible value — Value
- ROE of only -43.0% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Bollinger bandwidth of 30.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
59/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 54%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 8.4x prices in significant intangible value
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 74 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 30.3% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
74.4
Overbought
MACD Histogram
6.862
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Lh Ll
Bollinger %B
0.99
Inside Bands
Price vs Moving Averages
EMA 9
$343.98
Above
EMA 21
$329.04
Above
EMA 50
$319.66
Above
EMA 200
$273.58
Above
Fundamental Analysis
Valuation
33
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-28.6×
P/B Ratio
8.05×
PEG Ratio
5.09
Dividend Yield
0.00%
52W High
$382.54
52W Low
$37.19
Quality & Growth
ROE
-3453.5%
ROA
-3233.4%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -28.6 (inexpensive relative to a 15-40x range); Price-to-book of 8.1x; PEG ratio of 5.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -34.5%; Return on assets of -32.3%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 15.73 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-10.50); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full PRAX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →